199 related articles for article (PubMed ID: 21680240)
1. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
Zara G; Zambello R; Ermani M
Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
3. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
4. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
5. Worsening after rituximab treatment in anti-mag neuropathy.
Broglio L; Lauria G
Muscle Nerve; 2005 Sep; 32(3):378-9. PubMed ID: 15986418
[No Abstract] [Full Text] [Related]
6. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
7. Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody.
Rech J; Hueber AJ; Kallert S; Leipe J; Kalden JR; Beck M; Schett G; Schulze-Koops H
Ther Apher Dial; 2008 Jun; 12(3):205-8. PubMed ID: 18503697
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.
Renaud S; Gregor M; Fuhr P; Lorenz D; Deuschl G; Gratwohl A; Steck AJ
Muscle Nerve; 2003 May; 27(5):611-5. PubMed ID: 12707982
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of rituximab in anti-mag polyneuropathy.
Benedetti L; Briani C; Franciotta D; Carpo M; Padua L; Zara G; Zambello R; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
Neurology; 2008 Nov; 71(21):1742-4. PubMed ID: 19015493
[No Abstract] [Full Text] [Related]
10. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
[TBL] [Abstract][Full Text] [Related]
11. NK cells and their receptors in naive and rituximab-treated patients with anti-MAG polyneuropathy.
Benedetti L; Facco M; Franciotta D; Dalla Torre C; Campagnolo M; Lucchetta M; Boscaro E; Ermani M; Del Sette M; Berno T; Candiotto L; Zambello R; Briani C
J Neurol Sci; 2013 Aug; 331(1-2):86-9. PubMed ID: 23764364
[TBL] [Abstract][Full Text] [Related]
12. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
13. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
Gruson B; Ghomari K; Beaumont M; Garidi R; Just A; Merle P; Merlusca L; Marolleau JP; Royer B
J Peripher Nerv Syst; 2011 Sep; 16(3):180-5. PubMed ID: 22003932
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
15. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment.
Campagnolo M; Ferrari S; Dalla Torre C; Cabrini I; Cacciavillani M; Lucchetta M; Ruggero S; Toffanin E; Cavallaro T; Briani C
J Neuroimmunol; 2015 Apr; 281():1-4. PubMed ID: 25867460
[TBL] [Abstract][Full Text] [Related]
16. Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy.
Benedetti L; Franciotta D; Vigo T; Grandis M; Fiorina E; Ghiglione E; Roccatagliata L; Mancardi GL; Uccelli A; Schenone A
Arch Neurol; 2007 Oct; 64(10):1531-3. PubMed ID: 17923639
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
18. B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy.
Benedetti L; Zardini E; Briani C; Beronio A; Gastaldi S; Jarius S; Mancardi GL; Schenone A; Franciotta D
J Neurol Neurosurg Psychiatry; 2011 Nov; 82(11):1291-4. PubMed ID: 21172861
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports.
Souayah N; Noopur R; Tick-Chong PS
Immunopharmacol Immunotoxicol; 2013 Oct; 35(5):622-4. PubMed ID: 23944288
[TBL] [Abstract][Full Text] [Related]
20. Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment.
Stork AC; Notermans NC; Vrancken AF; Cornblath DR; van der Pol WL
J Peripher Nerv Syst; 2013 Jun; 18(2):189-91. PubMed ID: 23781968
[No Abstract] [Full Text] [Related]
[Next] [New Search]
